Structures by: Smith M. G.
Total: 8
(N'-(diphenylmethylene)isonicotinohydrazide)_(salicylic acid)
C19H15N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=25.8071(6)Å b=6.9240(2)Å c=12.2426(3)Å
α=90° β=103.5010(10)° γ=90°
(N'-(bis(2-hydroxyphenyl)methylene)isonicotinohydrazide)_(salicyclic acid)
C19H15N3O3,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=25.010(2)Å b=6.9708(7)Å c=12.4779(11)Å
α=90° β=90.949(6)° γ=90°
(N'-(di-p-tolylmethylene)isonicotinohydrazide)_(salicyclic acid) Form I
C21H19N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=9.9062(2)Å b=12.0906(3)Å c=12.4633(3)Å
α=113.5360(10)° β=113.0770(10)° γ=96.2970(10)°
(N'-(di-p-tolylmethylene)isonicotinohydrazide)_(salicylic acid) Form II
C21H19N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=8.2520(3)Å b=11.2852(4)Å c=12.9411(5)Å
α=77.516(2)° β=85.880(2)° γ=82.910(2)°
((E)-N'-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide)_ (salicylic acid)
C21H20N4O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=7.0057(4)Å b=11.5495(7)Å c=15.6046(9)Å
α=87.598(4)° β=82.792(4)° γ=72.850(3)°
((E)-N'-(phenyl(p-tolyl)methylene)isonicotinohydrazide)_(salicyclic acid),
C20H17N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=6.6193(2)Å b=12.3234(3)Å c=14.4180(3)Å
α=98.727(2)° β=98.596(2)° γ=100.665(2)°
(E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)_(salicylic acid)
C19H16N4O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=9.2815(3)Å b=11.7198(3)Å c=12.2187(3)Å
α=94.4050(10)° β=110.971(2)° γ=113.076(2)°
(E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)_(salicylic acid)
C19H16N4O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=7.8452(3)Å b=10.7034(4)Å c=13.1775(5)Å
α=90° β=93.234(3)° γ=90°